Drugs targeting the glucagon-like peptide 1 receptor (GLP-1R) offer several positive effects for individuals with type 2 diabetes, including the lowering of blood glucose and the reduction of body weight and of cardiovascular risk. In a study in mice, researchers at KI SÖS and Södersjukhuset have shown that the specific weight-loss properties of these treatments are key to also improving neurological recovery after suffering from stroke.
This article was originally published on MedicalXpress.com
